{"disease":{"id":"extensively-drug-resistant-tuberculosis","name":"extensively drug resistant tuberculosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00685360","title":"A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":481,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT04062201","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":402,"lead_sponsor_name":"Wits Health Consortium (Pty) Ltd","has_results":false},{"nct_id":"NCT04081077","title":"PRACTECAL-PKPD Sub Study","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Medecins Sans Frontieres, Netherlands","has_results":false},{"nct_id":"NCT01071603","title":"Tuberculosis in China","phase":"","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03086486","title":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":181,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT02454205","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"University of Cape Town","has_results":false},{"nct_id":"NCT01212003","title":"Training Protocol on the Natural History of Tuberculosis","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04207112","title":"Economic Evaluation of New MDR TB Regimens","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Medecins Sans Frontieres, Netherlands","has_results":false},{"nct_id":"NCT01381757","title":"Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali","phase":"","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}